

San Francisco Spring Group Meeting

SPECIALS

Prevention, Screening, and Surveillance
Committee

Prevention, Screening, & Surveillance Committee

Leadership

Co-Chairs: Banu Arun, MD
..... Jason A. Zell, DO

Time/Location

Thursday, May 1, 2025 4:30 p.m. - 6:30 p.m.
Room: Bayview Room (Bay Level)

Agenda

Welcome and Opening Comments

Dr. Jason Zell & Dr. Banu Arun

Frank and Linda Meyskens Annual Endowed Lectureship on Advances in Cancer Prevention: "A Third of a Century Experience in Design, Execution, Analysis, Reporting, and Long-Term Follow-Up of Pivotal Cancer Prevention Trials"
Ian M. Thompson, Jr., MD, Children's Hospital of San Antonio

Closed Studies

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. J. Zell, P. Brown, M.P. Lance, et al. Activated: 3/1/13. Closed: 6/30/23.

S1823, "A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors". Drs. C. Nichols and L. Nappi. Activated: 6/1/20. Closed: 5/20/24.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. K. Crew, R. Kukafka, et al. Activated 9/1/20. Closed 6/14/24.

Concepts in Development (not yet approved by Triage)

Concept, "Randomized trial of Radiation with or without HER2 targeted therapy (trastuzumab) in DCIS patients identified as Residual Risk (RR) by DCISionRT testing". Dr. E. Connolly.

- Concept received feedback from Patient Advocate Committee
- Concept pending drug availability through CTEP.

SWOG/Alliance Tamoxifen/Exemestane Concept, Dr. J. McGuinness.

Other Group Studies with SWOG Study Champions

CTSU A151804, "Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events." Dr. G. Lyman. Activated: 1/31/20.

CTSU A212102, "Blinded Reference Set for Multicancer Early Detection Blood Tests." Dr. J. McGuinness. Activated: 8/1/22.

CTSU EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. B. Arun. Activated: 7/6/17.

CTSU/NHLBI-MDS, "The National Myelodysplastic Syndromes (MDS) Study." Drs. D. Hill and C. Arana Yi. Activated: 4/5/16. Closed: 6/24/24.

CTSU/EA8184, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

CTSU/NRG-CC005, "FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)". Dr. L. Kachnic. Activated: 10/6/21.

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2024 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

S9217/S0000 Long-term side effects and complications after prostate cancer treatment.Unger J, Till C, Tangen C, Hershman D, Goodman P, Leblanc M, Barlow W, Vaidya R, Minasian L, Parnes H, Thompson IM. JAMA Oncology Nov 7;10(12):1654-1662, 2024.
<https://pubmed.ncbi.nlm.nih.gov/39509091/>

Multiple Studies* Stern M, Sanchez Mendez J, Kim A, Obon-Santacana M, Moratalla-Navarro F, Martin V, Moreno V, Lin Y, Bien S, Qu C, Su Y, White E, Harrison T, Huyghe J, Tangen C, Newcomb P, Phipps A, Thomas C, Kawaguchi E, Lewinger J, Morrison J, Conti D, Wang J, Thomas D, Platz E, Visvanathan K, Keku T, Newton C, Um C, Kundaje A, Shcherbina A, Murphy N, Gunter M, Dimou N, Papadimitriou N, Bezieau S, van Duijnhoven F, Mannisto S, Rennert G, Wolk A, Hoffmeister M, Brenner H, Chang-Claude J, Tian Y, LeMarchand L, Cotterchio M, Tsilidis K, Bishop D, Melaku Y, Lynch B, Buchanan D, Ulrich C, Ose J, Peoples A, Pellatt A, Devall M, Campbell P, Albanes D, Weinstein S, Berndt S, Gruber S, Ruiz-Narvaez E, SongM, Joshi A, Drew D, Petrick J, Chan A, Giannakis

Prevention, Screening, & Surveillance Committee

M, Peters U, Hsu L, Gauderman W. Genome-Wide Gene-Environment Interaction Analyses to Understand the Relationship between Red Meat and Processed Meat Intake and Colorectal Cancer Risk. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION Mar 1;33(3):400-410, 2024.
[*S9217, OTHER] <https://pubmed.ncbi.nlm.nih.gov/38112776/>

Submitted Manuscripts

None this cycle

Prevention, Screening, and Surveillance Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	<i>S1823</i>	<i>S1904</i>	<i>A211801</i>	<i>A212102</i>	<i>EA1151</i>	<i>EA2185</i>	<i>EA8184</i>	<i>NRGCC005</i>	<i>NRGCC008</i>
<i>Audie L Murphy VA Hospital</i>	-	-	-	34	-	-	4	-	-
<i>Banner MD Anderson Cancer Center</i>	5	-	-	-	1	-	-	-	-
<i>Banner University Medical Center - Tucson</i>	14	-	-	-	56	-	-	-	-
<i>Baptist Memorial Health Care/Mid S Minority Underserved NCORP</i>	-	12	-	-	8	-	-	-	-
<i>Bay Area Tumor Institute NCORP</i>	1	-	-	-	-	-	-	-	-
<i>Baylor College of Medicine/Duncan Comprehensive Cancer Center</i>	-	-	-	-	-	3	-	-	4
<i>CWRU Case Comprehensive Cancer Center LAPS</i>	-	-	-	2	290	-	-	-	-
<i>Cancer Research Consortium of West Michigan NCORP</i>	2	-	-	-	-	-	-	-	-
<i>Cancer Research for the Ozarks NCORP</i>	5	-	-	-	-	-	-	-	-
<i>Cancer Research of Wisconsin and Northern Michigan Consortium</i>	6	-	-	-	-	-	-	-	-
<i>Carle Cancer Center NCI Community Oncology Research Program</i>	5	26	-	-	2	-	-	-	-
<i>City of Hope Comprehensive Cancer Center</i>	-	20	-	-	-	-	-	-	-
<i>Columbia University Minority Underserved NCORP</i>	-	42	-	-	-	-	-	-	-
<i>Columbus NCI Community Oncology Research Program</i>	7	-	-	-	-	-	-	-	-
<i>Essentia Health NCI Community Oncology Research Program</i>	5	-	-	-	100	-	-	-	-
<i>Grupo Oncologico Cooperativo de Investigacion</i>	-	-	-	-	105	-	-	-	-
<i>Gulf South Minority Underserved NCORP</i>	13	-	-	-	-	-	-	-	2
<i>Hawaii Minority Underserved NCORP</i>	3	21	-	-	80	-	-	-	-
<i>Heartland Cancer Research NCORP</i>	15	11	-	-	-	-	-	-	-
<i>Henry Ford Hospital</i>	-	-	-	4	133	-	-	-	-
<i>Kaiser Permanente NCI Community Oncology Research Program</i>	178	15	-	-	-	-	-	-	-
<i>Kansas City Veterans Affairs Medical Center</i>	-	-	-	2	-	-	-	1	-
<i>Lahey Hospital and Medical Center</i>	-	3	-	-	-	-	-	-	-
<i>Loma Linda University Medical Center</i>	8	-	-	-	-	-	-	-	-
<i>Loyola University Medical Center</i>	-	4	-	-	-	-	-	-	-
<i>Malcom Randall Veterans Administration Medical Center</i>	-	-	-	-	-	-	-	1	-
<i>Massachusetts VetS Epidemiology Research and Information Cntr</i>	-	-	-	26	-	8	-	16	-
<i>Medical University of South Carolina Minority Underserved NCORP</i>	-	-	-	1	4	-	3	-	-
<i>Memorial Hermann Texas Medical Center</i>	-	-	-	-	8	-	-	-	-
<i>NCORP of the Carolinas (Prisma Health NCORP)</i>	11	-	-	-	463	-	-	-	-
<i>Nevada Cancer Research Foundation NCORP</i>	1	-	-	-	-	-	-	-	-
<i>New Mexico Minority Underserved NCORP</i>	12	-	-	-	-	-	-	-	-
<i>Northwell Health NCORP</i>	11	-	-	-	-	-	-	-	1
<i>Ohio State University Comprehensive Cancer Center LAPS</i>	8	2	-	-	-	-	-	-	-

Prevention, Screening, and Surveillance Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	<i>S1823</i>	<i>S1904</i>	<i>A211801</i>	<i>A212102</i>	<i>EA1151</i>	<i>EA2185</i>	<i>EA8184</i>	<i>NRGCC005</i>	<i>NRGCC008</i>
<i>Oregon Health and Science University</i>	17	-	-	-	-	3	2	10	3
<i>Pacific Cancer Research Consortium NCORP</i>	-	1	-	-	-	-	-	-	-
<i>Riverside Methodist Hospital</i>	3	-	-	-	-	-	-	-	-
<i>Salem Hospital</i>	3	-	-	-	-	-	-	-	-
<i>Southeast Clinical Oncology Research Consortium NCORP</i>	2	-	-	-	-	-	-	-	-
<i>The Don and Sybil Harrington Cancer Center</i>	-	-	-	5	-	-	-	-	-
<i>Tulane University School of Medicine</i>	-	-	-	-	2	-	-	-	-
<i>UC Davis Comprehensive Cancer Center LAPS</i>	-	-	-	-	-	1	1	-	-
<i>UC Irvine Health/Chao Family Comprehensive Cancer Center</i>	4	-	-	76	-	-	-	-	-
<i>UC San Diego Moores Cancer Center</i>	24	-	-	-	-	1	-	-	-
<i>UCLA / Jonsson Comprehensive Cancer Center</i>	30	-	-	-	-	-	-	-	-
<i>USC Norris Comprehensive Cancer Center LAPS</i>	33	-	-	-	-	-	-	-	-
<i>University of Arkansas for Medical Sciences</i>	-	-	-	-	389	3	-	-	-
<i>University of Cincinnati Cancer Center-UC Medical Center</i>	6	-	-	-	-	-	-	-	-
<i>University of Colorado Cancer Center LAPS</i>	26	-	-	5	2	-	-	8	-
<i>University of Kentucky/Markey Cancer Center</i>	-	-	-	-	9	-	-	-	-
<i>University of Michigan Comprehensive Cancer Center LAPS</i>	-	-	1	-	-	-	-	-	-
<i>University of Mississippi Medical Center</i>	6	-	-	-	-	-	-	-	-
<i>University of Oklahoma Health Sciences Center LAPS</i>	8	-	-	-	-	-	-	-	-
<i>University of Rochester LAPS</i>	20	-	-	-	263	-	-	-	-
<i>University of Texas Health Science Center at San Antonio</i>	-	-	-	19	-	-	-	-	1
<i>University of Utah - Huntsman Cancer Institute LAPS</i>	-	21	-	-	-	-	-	-	-
<i>Upstate Carolina NCORP</i>	-	-	-	-	619	-	-	-	-
<i>Vanderbilt University - Ingram Cancer Center LAPS</i>	7	-	-	-	-	-	-	-	-
<i>Virginia Mason Medical Center</i>	16	-	-	-	-	-	-	-	-
<i>Wayne State University - Karmanos Cancer Institute LAPS</i>	-	-	-	-	8	-	-	-	-
<i>Western States Cancer Research NCORP</i>	5	-	-	-	73	-	-	-	-
<i>ALLIANCE</i>	96	106	-	-	-	-	-	-	-
<i>CCTG</i>	217	-	-	-	-	-	-	-	-
<i>ECOG-ACRIN</i>	76	43	-	-	-	-	-	-	-
<i>NRG</i>	55	85	-	-	-	-	-	-	-
Total	964	412	1	174	2,615	19	10	36	11

